Compare Fox Corp Class B (FOX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Novartis AG — how do they compare? Fox Corp Class B trades at $50.9 (market cap $22.28B), while Novartis AG trades at $152.92 (market cap $287.66B). The key difference: Novartis AG is far larger — about 12.9× Fox Corp Class B's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| FOX | NVS | |
|---|---|---|
Market Cap | $22.28B | $287.66B |
Sector | Media | Health |
52-Week High | $67.76 | $168.62 |
52-Week Low | $44.39 | $113.50 |
Enterprise Value | $26.25B | $327.68B |
Dividend Yield | 1.11% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOX) trades at $51.06, up 3.15% with strong recent earnings beats. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, the company delivered robust 2025 results with $16.3B revenue and $2.26B net income, supported by improved cash flow generation. Recent news highlights Fox's strategic positioning in streaming and advertising growth.
Fox presents a compelling value opportunity with reasonable valuation multiples (P/E 13.26, P/S 1.39) and consistent earnings outperformance. However, technical weakness and competitive pressures in media streaming require monitoring. Analyst consensus leans positive with 42.86% buy ratings, though execution risks in the Roku integration and advertising market volatility remain key considerations.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
